PL2822555T3 - Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu - Google Patents

Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu

Info

Publication number
PL2822555T3
PL2822555T3 PL13709722T PL13709722T PL2822555T3 PL 2822555 T3 PL2822555 T3 PL 2822555T3 PL 13709722 T PL13709722 T PL 13709722T PL 13709722 T PL13709722 T PL 13709722T PL 2822555 T3 PL2822555 T3 PL 2822555T3
Authority
PL
Poland
Prior art keywords
pain
inhibition
treatment
associated kinase
adaptor associated
Prior art date
Application number
PL13709722T
Other languages
English (en)
Polish (pl)
Inventor
Thomas Herbert Lanthorn
Katerina Savelieva
Brian Zambrowicz
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PL2822555T3 publication Critical patent/PL2822555T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL13709722T 2012-03-09 2013-03-06 Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu PL2822555T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608849P 2012-03-09 2012-03-09
EP13709722.6A EP2822555B1 (en) 2012-03-09 2013-03-06 Inhibition of adaptor associated kinase 1 for the treatment of pain
PCT/US2013/029258 WO2013134336A2 (en) 2012-03-09 2013-03-06 Inhibition of adaptor associated kinase 1 for the treatment of pain

Publications (1)

Publication Number Publication Date
PL2822555T3 true PL2822555T3 (pl) 2018-04-30

Family

ID=47884616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13709722T PL2822555T3 (pl) 2012-03-09 2013-03-06 Inhibicja związanej z adaptorem kinazy-1 dla leczenia bólu

Country Status (14)

Country Link
US (4) US20140080834A1 (OSRAM)
EP (2) EP3235499A3 (OSRAM)
JP (1) JP2015513557A (OSRAM)
CN (1) CN104220071A (OSRAM)
AU (1) AU2013230066A1 (OSRAM)
CA (1) CA2866145A1 (OSRAM)
DK (1) DK2822555T3 (OSRAM)
ES (1) ES2657061T3 (OSRAM)
HK (1) HK1199814A1 (OSRAM)
HU (1) HUE036040T2 (OSRAM)
NO (1) NO2935475T3 (OSRAM)
PL (1) PL2822555T3 (OSRAM)
PT (1) PT2822555T (OSRAM)
WO (1) WO2013134336A2 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866164C (en) 2012-03-09 2020-07-07 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
IN2014DN07384A (OSRAM) 2012-03-09 2015-04-24 Lexicon Pharmaceuticals Inc
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
JP6434968B2 (ja) * 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
JP2016523963A (ja) 2013-07-08 2016-08-12 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company アリールアミドキナーゼ阻害剤
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015038112A1 (en) * 2013-09-11 2015-03-19 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
EP3054955B1 (en) 2013-10-11 2018-05-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP6441947B2 (ja) * 2014-01-31 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キノリンを基にしたキナーゼ阻害剤
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
ES2700549T3 (es) 2014-04-02 2019-02-18 Bristol Myers Squibb Co Inhibidores de biaril quinasa
CN107108552A (zh) * 2014-08-05 2017-08-29 百时美施贵宝公司 杂环激酶抑制剂
PT3215511T (pt) 2014-11-06 2024-05-22 Bial R&D Invest S A Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
ES2765730T3 (es) 2015-10-01 2020-06-10 Bristol Myers Squibb Co Inhibidores de biaril cinasa
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP7164774B2 (ja) 2016-05-05 2022-11-02 ビアル-アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ 置換イミダゾ[1,2-b]ピリダジン、置換イミダゾ[1,5-b]ピリダジン、関連化合物、および医学的障害の治療におけるその使用
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment
WO2025225608A1 (en) * 2024-04-23 2025-10-30 Otsuka Pharmaceutical Co., Ltd. Tetrahydropyrazolopyridine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2008052734A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
AU2009246687B2 (en) * 2008-05-13 2012-08-09 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2010028005A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Also Published As

Publication number Publication date
AU2013230066A1 (en) 2014-09-25
WO2013134336A2 (en) 2013-09-12
PT2822555T (pt) 2018-01-25
DK2822555T3 (en) 2018-02-05
HK1199814A1 (en) 2015-07-24
EP3235499A3 (en) 2018-01-17
CA2866145A1 (en) 2013-09-12
ES2657061T3 (es) 2018-03-01
EP2822555A2 (en) 2015-01-14
EP3235499A2 (en) 2017-10-25
US20150164899A1 (en) 2015-06-18
CN104220071A (zh) 2014-12-17
HUE036040T2 (hu) 2018-06-28
WO2013134336A3 (en) 2014-03-06
NO2935475T3 (OSRAM) 2017-12-16
US20160206619A1 (en) 2016-07-21
US20140080834A1 (en) 2014-03-20
EP2822555B1 (en) 2017-11-08
US20190134037A1 (en) 2019-05-09
JP2015513557A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
HUE036040T2 (hu) Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
ZA201208646B (en) Pharmaceutical combination for the treatment of pain
ZA201408055B (en) Compositions and methods for the treatment of local pain
SMT201800604T1 (it) Composti per il trattamento di obesita' e metodi di uso degli stessi
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2970118A4 (en) COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
PL399422A1 (pl) Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu
PL399423A1 (pl) Sposób wytwarzania 2'-hydroksydihydrochalkonu